CD274 and cancer: Similar to our interest, the role of epigenetic modifiers in sensitizing cancers to different therapeutics [22], in particular the use of combination treatment to augment PD-L1 targeted immunotherapies [23], has been in consideration for quite some time in many other laboratories.